ABT – Abbott Laboratories
Float Short %
Margin Of Safety %
20
Put/Call OI Ratio
1.16
EPS Next Q Diff
-0.1
EPS Last/This Y
-2.5
EPS This/Next Y
0.51
Price
108.62
Target Price
145.46
Analyst Recom
1.77
Performance Q
-14.84
Relative Volume
5.83
Beta
0.75
Ticker: ABT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | ABT | 124.85 | 0.88 | 0.60 | 194644 |
| 2025-12-29 | ABT | 124.61 | 0.88 | 0.86 | 192966 |
| 2025-12-30 | ABT | 125.81 | 0.89 | 0.45 | 194528 |
| 2025-12-31 | ABT | 125.28 | 0.90 | 1.35 | 197991 |
| 2026-01-02 | ABT | 124.2 | 0.91 | 1.38 | 199425 |
| 2026-01-05 | ABT | 126.46 | 0.88 | 0.76 | 194904 |
| 2026-01-06 | ABT | 127.82 | 0.88 | 1.09 | 196388 |
| 2026-01-07 | ABT | 127.04 | 0.88 | 1.96 | 200693 |
| 2026-01-08 | ABT | 126.19 | 0.90 | 0.94 | 205658 |
| 2026-01-09 | ABT | 125.89 | 0.91 | 1.19 | 206819 |
| 2026-01-12 | ABT | 124.64 | 0.92 | 0.85 | 199957 |
| 2026-01-13 | ABT | 124.25 | 0.92 | 1.55 | 205385 |
| 2026-01-14 | ABT | 125 | 0.93 | 0.03 | 206936 |
| 2026-01-15 | ABT | 123.52 | 0.97 | 5.90 | 204775 |
| 2026-01-16 | ABT | 121.76 | 0.95 | 1.13 | 205072 |
| 2026-01-20 | ABT | 121.11 | 1.13 | 1.77 | 126615 |
| 2026-01-21 | ABT | 120.76 | 1.13 | 1.61 | 134691 |
| 2026-01-22 | ABT | 108.61 | 1.16 | 2.56 | 154752 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | ABT | 124.84 | 11.6 | 2889.6 | 5.17 |
| 2025-12-29 | ABT | 124.60 | 11.6 | 2864.8 | 5.17 |
| 2025-12-30 | ABT | 125.83 | 11.6 | 3000.9 | 5.17 |
| 2025-12-31 | ABT | 125.29 | 11.6 | 2843.5 | 5.17 |
| 2026-01-02 | ABT | 124.20 | 11.6 | 2789.0 | 5.17 |
| 2026-01-05 | ABT | 126.46 | 11.6 | 3092.4 | 5.17 |
| 2026-01-06 | ABT | 127.80 | 11.6 | 3007.3 | 5.17 |
| 2026-01-07 | ABT | 127.04 | 11.6 | 2821.3 | 5.17 |
| 2026-01-08 | ABT | 126.18 | 11.6 | 2810.7 | 5.17 |
| 2026-01-09 | ABT | 125.89 | 11.6 | 2860.6 | 5.17 |
| 2026-01-12 | ABT | 124.65 | 11.6 | 2773.3 | 5.17 |
| 2026-01-13 | ABT | 124.28 | 11.6 | 2854.4 | 5.17 |
| 2026-01-14 | ABT | 125.02 | 11.6 | 2952.2 | 5.17 |
| 2026-01-15 | ABT | 123.46 | 11.6 | 2748.7 | 5.17 |
| 2026-01-16 | ABT | 121.76 | 11.6 | 2725.6 | 5.17 |
| 2026-01-20 | ABT | 121.10 | 11.6 | 2826.0 | 5.17 |
| 2026-01-21 | ABT | 120.79 | 11.6 | 2854.4 | 5.17 |
| 2026-01-22 | ABT | 108.62 | 11.6 | 1758.0 | 5.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | ABT | -0.06 | 0.19 | 0.92 |
| 2025-12-29 | ABT | -0.06 | 0.19 | 0.92 |
| 2025-12-30 | ABT | -0.06 | 0.19 | 0.92 |
| 2025-12-31 | ABT | -0.06 | 0.19 | 0.92 |
| 2026-01-02 | ABT | -0.06 | 0.19 | 0.92 |
| 2026-01-05 | ABT | -0.06 | 0.21 | 0.92 |
| 2026-01-06 | ABT | -0.06 | 0.21 | 0.92 |
| 2026-01-07 | ABT | -0.06 | 0.21 | 0.92 |
| 2026-01-08 | ABT | -0.06 | 0.21 | 0.92 |
| 2026-01-09 | ABT | -0.06 | 0.21 | 0.92 |
| 2026-01-12 | ABT | -0.06 | 0.19 | 0.92 |
| 2026-01-13 | ABT | -0.06 | 0.19 | 1.01 |
| 2026-01-14 | ABT | -0.06 | 0.19 | 1.01 |
| 2026-01-15 | ABT | -0.06 | 0.19 | 1.01 |
| 2026-01-16 | ABT | -0.06 | 0.19 | 1.01 |
| 2026-01-20 | ABT | -0.06 | 0.32 | 1.01 |
| 2026-01-21 | ABT | -0.06 | 0.32 | 1.01 |
| 2026-01-22 | ABT | -0.06 | 0.32 | 0 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.3
Avg. EPS Est. Current Quarter
1.5
Avg. EPS Est. Next Quarter
1.2
Insider Transactions
-0.06
Institutional Transactions
0.32
Beta
0.75
Average Sales Estimate Current Quarter
11798
Average Sales Estimate Next Quarter
11196
Fair Value
130.4
Quality Score
98
Growth Score
86
Sentiment Score
50
Actual DrawDown %
23.8
Max Drawdown 5-Year %
-33.9
Target Price
145.46
P/E
29.33
Forward P/E
17.32
PEG
1.65
P/S
4.26
P/B
3.71
P/Free Cash Flow
27.3
EPS
3.7
Average EPS Est. Cur. Y
5.17
EPS Next Y. (Est.)
5.68
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
14.61
Relative Volume
5.83
Return on Equity vs Sector %
0.2
Return on Equity vs Industry %
9.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
1758
Abbott LaboratoriesSector: Healthcare
Industry: Medical Devices
Employees:
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
stock quote shares ABT – Abbott Laboratories Stock Price stock today
news today ABT – Abbott Laboratories stock forecast ,stock prediction 2023 2024 2025
marketwatch ABT – Abbott Laboratories yahoo finance google finance
stock history ABT – Abbott Laboratories invest stock market
stock prices ABT premarket after hours
ticker ABT fair value insiders trading